• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转移性透明细胞肾细胞癌:伪装高手与巨大困境

Metastatic Clear Cell Renal Cell Carcinoma: The Great Pretender and the Great Dilemma.

作者信息

Maestroni Umberto, Gasparro Donatello, Ziglioli Francesco, Guarino Giulio, Campobasso Davide

机构信息

Department of Urology, University Hospital of Parma/Azienda Ospedaliero-Universitaria di Parma, Via Gramsci 14, Parma 43126, Italy.

Medical Oncology Unit, University Hospital of Parma/Azienda Ospedaliero-Universitaria di Parma, Via Gramsci 14, Parma 43126, Italy.

出版信息

World J Oncol. 2021 Oct;12(5):178-182. doi: 10.14740/wjon1406. Epub 2021 Oct 21.

DOI:10.14740/wjon1406
PMID:34804281
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8577602/
Abstract

Metastatic renal cell carcinoma (mRCC) may present with a wide range of clinical pictures. Reportedly, paraneoplastic syndromes are the first sign in 20% of cases and only 15% of cases show the classic triad (flank pain, gross hematuria, and palpable abdominal mass) at presentation. The remaining cases present with signs and symptoms related to the site of distant metastases. These data may explain the reason why about 20-30% of patients are metastatic at presentation. We report the case of a 63-year-old woman who came to our attention for lower back pain. After imaging studies, we detected a left kidney mass of 86 × 61 × 79 mm, multiple right pulmonary nodules and six bone lesions. She underwent left radical nephrectomy. After 1 month, she developed signs of spinal cord compression with neurological deficits and she underwent emergency spinal decompression. In order to allow complete motor recovery, the subsequent stereotactic body radiation therapy was not performed, and she is currently taking combination immunotherapy regimens. Management of mRCC is in a continuous evolution due to availability of new target therapies and the possibility of a multimodal approach with surgical, focal and radiotherapy treatments. However, the ideal treatment algorithm is yet to come. This is why mRCC diagnosis and management are still challenging for the clinicians.

摘要

转移性肾细胞癌(mRCC)可能呈现出广泛的临床表现。据报道,副肿瘤综合征在20%的病例中是首发症状,仅有15%的病例在初诊时表现出典型三联征(胁腹痛、肉眼血尿和可触及的腹部肿块)。其余病例则表现出与远处转移部位相关的体征和症状。这些数据或许可以解释为何约20% - 30%的患者在初诊时就已发生转移。我们报告一例63岁女性患者,因下背部疼痛前来就诊。经影像学检查,我们发现左肾有一个大小为86×61×79 mm的肿块,右肺有多个结节以及6处骨病变。她接受了左肾根治性切除术。1个月后,她出现脊髓压迫症状及神经功能缺损,随后接受了急诊脊髓减压手术。为了实现完全的运动功能恢复,后续未进行立体定向体部放射治疗,她目前正在接受联合免疫治疗方案。由于新的靶向治疗方法的出现以及采用手术、局部治疗和放射治疗的多模式治疗方法的可能性,mRCC的治疗方法在不断演变。然而,理想的治疗方案尚未出现。这就是为什么mRCC的诊断和治疗对临床医生来说仍然具有挑战性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cbc/8577602/3a72dba3cfd4/wjon-12-178-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cbc/8577602/3847606bdd3c/wjon-12-178-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cbc/8577602/dff8c914e3bb/wjon-12-178-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cbc/8577602/3a72dba3cfd4/wjon-12-178-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cbc/8577602/3847606bdd3c/wjon-12-178-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cbc/8577602/dff8c914e3bb/wjon-12-178-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cbc/8577602/3a72dba3cfd4/wjon-12-178-g003.jpg

相似文献

1
Metastatic Clear Cell Renal Cell Carcinoma: The Great Pretender and the Great Dilemma.转移性透明细胞肾细胞癌:伪装高手与巨大困境
World J Oncol. 2021 Oct;12(5):178-182. doi: 10.14740/wjon1406. Epub 2021 Oct 21.
2
Papillary thyroid carcinoma presenting as a primary renal tumor with multiple pulmonary and bone metastases: a case report.表现为原发性肾肿瘤伴多发肺和骨转移的甲状腺乳头状癌:一例报告
J Med Case Rep. 2019 Apr 20;13(1):95. doi: 10.1186/s13256-019-2025-8.
3
[RENAL CELL CARCINOMA METASTASIS TO BLADDER DURING MOLECULAR TARGETED THERAPY WITH PAZOPANIB: REPORT OF TWO CASES].[帕唑帕尼分子靶向治疗期间肾细胞癌转移至膀胱:2例报告]
Nihon Hinyokika Gakkai Zasshi. 2020;111(2):58-61. doi: 10.5980/jpnjurol.111.58.
4
Nonmetastatic renal cell carcinoma presenting with persistent cough: Case report with literature review.以持续性咳嗽为表现的非转移性肾细胞癌:病例报告及文献复习
Avicenna J Med. 2019 Oct 3;9(4):160-163. doi: 10.4103/ajm.AJM_47_19. eCollection 2019 Oct-Dec.
5
Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy.传统放化疗治疗后疾病进展的难治性转移性肛管鳞状细胞癌的管理
J Adv Pract Oncol. 2012 May;3(3):161-9. doi: 10.6004/jadpro.2012.3.3.4.
6
[Renal cell carcinoma--a current review].[肾细胞癌——当前综述]
Praxis (Bern 1994). 1997 May 14;86(20):837-43.
7
A case of metastatic renal cell carcinoma to the ovary.一例卵巢转移性肾细胞癌病例。
Hinyokika Kiyo. 2006 Dec;52(12):923-7.
8
Paraneoplastic Encephalopathy in a Patient With Metastatic Lung Cancer: A Case Study.一名转移性肺癌患者的副肿瘤性脑病:病例报告
J Adv Pract Oncol. 2018 Mar;9(2):216-221. Epub 2018 Mar 1.
9
Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases.术前活检在转移性肾细胞癌患者中的局限性:405 例手术病理比较。
BJU Int. 2012 Dec;110(11):1742-6. doi: 10.1111/j.1464-410X.2012.11124.x. Epub 2012 Apr 13.
10
Stereotactic Radiotherapy for Cervical Spinal Intramedullary Metastasis and Multiple Brain Metastases: A Case Report.立体定向放射治疗颈椎髓内转移瘤和多发脑转移瘤:一例报告
Cureus. 2016 Apr 27;8(4):e590. doi: 10.7759/cureus.590.

引用本文的文献

1
Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment.转移性肾细胞癌中非常有利与有利风险组:迈向个性化治疗的一步。
Cancers (Basel). 2025 Mar 23;17(7):1076. doi: 10.3390/cancers17071076.
2
Late Recurrence of Renal Cell Carcinoma in Unusual Sites 23 Years After Nephrectomy.肾切除术后23年罕见部位肾细胞癌的晚期复发
Cureus. 2023 Sep 21;15(9):e45707. doi: 10.7759/cureus.45707. eCollection 2023 Sep.
3
World Journal of Oncology Has Gained an Impact Factor of 5.2 by Journal Citation Reports.

本文引用的文献

1
The role of imaging in the management of renal masses.影像学在肾肿块管理中的作用。
Eur J Radiol. 2021 Aug;141:109777. doi: 10.1016/j.ejrad.2021.109777. Epub 2021 May 15.
2
Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice.转移性肾细胞癌的管理:从分子机制到临床实践
Front Oncol. 2021 Apr 22;11:657639. doi: 10.3389/fonc.2021.657639. eCollection 2021.
3
Level IV tumor thrombus in non-metastatic renal cell cancer? No, thanks. Level II is better. Lessons learned from a case report.
《世界肿瘤学杂志》在《期刊引证报告》中获得了5.2的影响因子。
World J Oncol. 2023 Aug;14(4):231-233. doi: 10.14740/wjon1687. Epub 2023 Aug 4.
4
When should surgery be used to supplement systemic therapy in metastatic renal cell cancer?在转移性肾细胞癌中,何时应采用手术来辅助全身治疗?
J Thorac Dis. 2023 Jun 30;15(6):2896-2898. doi: 10.21037/jtd-23-457. Epub 2023 Jun 5.
5
Aberrant expression of polo-like kinase 4 in renal cell carcinoma: Association with clinicopathological characteristics and long-term survival.肾细胞癌中polo样激酶4的异常表达:与临床病理特征及长期生存的关系
Oncol Lett. 2022 Oct 14;24(6):427. doi: 10.3892/ol.2022.13547. eCollection 2022 Dec.
6
Metastatic renal cell carcinoma presenting as chronic bleeding from the stomach: a rare case report.以胃慢性出血为表现的转移性肾细胞癌:一例罕见病例报告
J Surg Case Rep. 2022 Feb 22;2022(2):rjac045. doi: 10.1093/jscr/rjac045. eCollection 2022 Feb.
7
The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?循环生物标志物在转移性肾细胞癌肿瘤管理中的作用:我们目前的进展如何?
Biomedicines. 2021 Dec 31;10(1):90. doi: 10.3390/biomedicines10010090.
非转移性肾细胞癌中的IV级肿瘤血栓?不,谢谢。II级更好。从一例病例报告中吸取的教训。
Urol Case Rep. 2021 Mar 25;37:101660. doi: 10.1016/j.eucr.2021.101660. eCollection 2021 Jul.
4
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature.细胞减灭性肾切除术在转移性肾细胞癌的靶向治疗和免疫治疗时代:一个难以捉摸的问题吗?系统文献复习。
Crit Rev Oncol Hematol. 2021 Apr;160:103293. doi: 10.1016/j.critrevonc.2021.103293. Epub 2021 Mar 2.
5
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.评估透明细胞癌、乳头状癌和嫌色细胞肾癌的转移部位及其与生存的关系。
JAMA Netw Open. 2021 Jan 4;4(1):e2021869. doi: 10.1001/jamanetworkopen.2020.21869.
6
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma.透明细胞转移性肾细胞癌治疗排序新算法的需求。
Expert Rev Anticancer Ther. 2021 Apr;21(4):401-412. doi: 10.1080/14737140.2021.1861941. Epub 2020 Dec 23.
7
Imaging guided percutaneous renal biopsy: do it or not?影像学引导下经皮肾活检:做还是不做?
Acta Biomed. 2020 Jul 13;91(8-S):81-88. doi: 10.23750/abm.v91i8-S.9990.
8
Epidemiology of Renal Cell Carcinoma.肾细胞癌的流行病学
World J Oncol. 2020 Jun;11(3):79-87. doi: 10.14740/wjon1279. Epub 2020 May 14.
9
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.寡转移和寡进展性肾细胞癌的管理:现状与未来方向。
Expert Rev Anticancer Ther. 2020 Jun;20(6):491-501. doi: 10.1080/14737140.2020.1770601. Epub 2020 Jun 1.
10
Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis.免疫治疗联合方案与转移性透明细胞肾细胞癌的标准一线治疗比较:系统评价和荟萃分析。
Clin Transl Oncol. 2020 Sep;22(9):1657-1663. doi: 10.1007/s12094-020-02292-z. Epub 2020 Jan 19.